Chimeric Antigen Receptor T-cell therapy

URI: https://gptkb.org/entity/Chimeric_Antigen_Receptor_T-cell_therapy
GPTKB entity
Statements (50)
Predicate Object
gptkbp:instanceOf gptkb:cancer
immunotherapy
gptkbp:abbreviation gptkb:CAR-T_therapy
gptkbp:administeredBy intravenous infusion
gptkbp:approvalYear 2017
gptkbp:approvedBy gptkb:FDA
gptkbp:category personalized medicine
cellular therapy
gptkbp:countryOfOperation gptkb:China
gptkb:European_Union
gptkb:United_States
gptkbp:developedBy gptkb:Carl_June
gptkb:Michel_Sadelain
gptkbp:firstPatientTreatedYear 2010
https://www.w3.org/2000/01/rdf-schema#label Chimeric Antigen Receptor T-cell therapy
gptkbp:limitation high cost
limited efficacy in solid tumors
complex manufacturing process
gptkbp:marketedAs gptkb:Carvykti
gptkb:Abecma
gptkb:Tecartus
gptkb:Kymriah
gptkb:Yescarta
gptkb:Breyanzi
gptkbp:mechanismOfAction genetically engineered T cells express chimeric antigen receptors
gptkbp:notableCase gptkb:CARTITUDE-1_trial
gptkb:ELIANA_trial
gptkb:JULIET_trial
gptkb:KarMMa_trial
gptkb:TRANSCEND_trial
gptkb:ZUMA-1_trial
gptkbp:processor Modified T cells expanded and infused back
T cells collected from patient
T cells genetically modified ex vivo
gptkbp:relatedTo gene therapy
monoclonal antibody therapy
adoptive cell transfer
gptkbp:researchInterest gptkb:allogeneic_CAR-T_cells
reducing toxicity
expanding to solid tumors
improving persistence of CAR-T cells
gptkbp:sideEffect neurotoxicity
cytokine release syndrome
gptkbp:target gptkb:CD19
gptkb:BCMA
gptkbp:usedFor treatment of B-cell lymphoma
treatment of acute lymphoblastic leukemia
treatment of hematologic malignancies
gptkbp:bfsParent gptkb:CAR-T_therapy
gptkbp:bfsLayer 7